Colgate-Palmolive (NYSE:CL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.

According to Zacks, “Colgate, which has lagged the industry in the past six months, witnessed strained margins lately. This stemmed from increased raw material and packaging costs, as well as higher advertising expenses. Further, it anticipates the aforementioned costs to persist and impact margins in 2017. Additionally, the company perked up its costs guidance related to charges arising from the expansion and extension of the Global Growth and Efficiency Program through Dec 31, 2019. This is also likely to put near-term pressure on the results.  Nonetheless, the company is encouraged by the progress and prospects from this program, with additional savings anticipated from this recent expansion. Also, the company with a meet or beat earnings track record, has been gaining from its robust brands portfolio and constant innovations. Colgate’s shareholder-friendly moves also remain noteworthy. Estimates have been stable lately ahead of fourth-quarter earnings.”

Other research analysts also recently issued research reports about the company. SunTrust Banks raised Colgate-Palmolive from a “hold” rating to a “buy” rating and raised their price objective for the stock from $65.00 to $85.00 in a research note on Wednesday, October 11th. Societe Generale downgraded Colgate-Palmolive from a “hold” rating to a “sell” rating and set a $66.00 price objective on the stock. in a research note on Wednesday, November 29th. They noted that the move was a valuation call. Citigroup decreased their price objective on Colgate-Palmolive from $76.00 to $75.00 and set a “neutral” rating on the stock in a research note on Thursday, November 2nd. Stifel Nicolaus set a $73.00 price objective on Colgate-Palmolive and gave the stock a “hold” rating in a research note on Sunday, October 29th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and issued a $74.00 price objective on shares of Colgate-Palmolive in a research note on Sunday, October 8th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $76.04.

Shares of Colgate-Palmolive (NYSE CL) traded down $0.06 during trading hours on Tuesday, reaching $73.99. The company’s stock had a trading volume of 3,252,300 shares, compared to its average volume of 3,601,951. The stock has a market capitalization of $65,023.70, a PE ratio of 25.80, a price-to-earnings-growth ratio of 3.39 and a beta of 0.81. The company has a debt-to-equity ratio of 24.42, a current ratio of 1.23 and a quick ratio of 0.92. Colgate-Palmolive has a fifty-two week low of $63.43 and a fifty-two week high of $77.27.

Colgate-Palmolive (NYSE:CL) last announced its earnings results on Friday, October 27th. The company reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. The business had revenue of $3.97 billion for the quarter, compared to analysts’ expectations of $3.94 billion. Colgate-Palmolive had a return on equity of 2,782.56% and a net margin of 15.10%. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period last year, the firm posted $0.73 earnings per share. equities analysts forecast that Colgate-Palmolive will post 2.88 earnings per share for the current year.

In related news, Director Stephen I. Sadove sold 20,780 shares of Colgate-Palmolive stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $70.52, for a total transaction of $1,465,405.60. Following the sale, the director now owns 36,268 shares of the company’s stock, valued at approximately $2,557,619.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Victoria L. Dolan sold 10,000 shares of Colgate-Palmolive stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $73.07, for a total value of $730,700.00. Following the sale, the insider now directly owns 60,528 shares in the company, valued at approximately $4,422,780.96. The disclosure for this sale can be found here. Insiders have sold a total of 181,048 shares of company stock worth $13,168,995 in the last three months. 1.02% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Colgate-Palmolive by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 67,875,384 shares of the company’s stock worth $5,031,602,000 after acquiring an additional 1,621,392 shares during the last quarter. Renaissance Technologies LLC increased its stake in Colgate-Palmolive by 42.4% in the 2nd quarter. Renaissance Technologies LLC now owns 9,753,400 shares of the company’s stock worth $723,020,000 after acquiring an additional 2,903,800 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Colgate-Palmolive by 25.3% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 6,854,323 shares of the company’s stock worth $508,111,000 after acquiring an additional 1,385,946 shares during the last quarter. First Eagle Investment Management LLC increased its stake in Colgate-Palmolive by 35.8% in the 3rd quarter. First Eagle Investment Management LLC now owns 6,641,548 shares of the company’s stock worth $483,837,000 after acquiring an additional 1,750,417 shares during the last quarter. Finally, Harding Loevner LP increased its stake in Colgate-Palmolive by 92.0% in the 3rd quarter. Harding Loevner LP now owns 4,742,752 shares of the company’s stock worth $176,329,000 after acquiring an additional 2,272,675 shares during the last quarter. 72.84% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/colgate-palmolive-cl-rating-lowered-to-sell-at-zacks-investment-research/1773194.html.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.

Analyst Recommendations for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.